Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848899 · ClinicalTrials.gov registry record · Phase 4
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT01848899 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 100 participants.
The verdict
NCT01848899, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet function in patients undergoing coronary angiography, and if the use of bivalirudin, a direct thrombin inhibitor used during percutaneous coronary intervention (PCI), affects any contrast-related changes in thrombogenesis and platelet function.
Interventions
- DRUG Bivalirudin
- DRUG Iodixanol
- DRUG Ioxaglate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01848899
The ClinicalTrials.gov registry entry for NCT01848899 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bivalirudin is the first listed.
NCT01848899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01848899 about?
NCT01848899 is a clinical study titled "Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography". The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet function in patients undergoing coronary angiography, and if the use of bival...
What is the current status of trial NCT01848899?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2013-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01848899?
The interventions under investigation include: Bivalirudin (DRUG), Iodixanol (DRUG), Ioxaglate (DRUG).
Who is sponsoring clinical trial NCT01848899?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.